Talphera (TLPH) 10-Q 11 Aug 22 2022 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2022	Aug. 05, 2022
Document Information [Line Items]
Entity Central Index Key	0001427925
Entity Registrant Name	ACELRX PHARMACEUTICALS INC
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2022
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2022
Document Transition Report	false
Entity File Number	001-35068
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	41-2193603
Entity Address, Address Line One	25821 Industrial Boulevard, Suite 400
Entity Address, City or Town	Hayward
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94545
City Area Code	650
Local Phone Number	216-3500
Title of 12(b) Security	Common Stock, $0.001 par value
Trading Symbol	ACRX
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		147,331,963

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021	[1]
Current Assets:
Cash and cash equivalents	$ 15,165	$ 7,663
Restricted cash	5,000	0
Short-term investments	7,758	38,967
Accounts receivable, net	364	160
Inventories, net	901	1,111
Prepaid expenses and other current assets	2,809	2,588
Total current assets	31,997	50,489
Operating lease right-of-use assets	3,985	4,302
Property and equipment, net	11,075	15,928
In-process research and development asset	8,819	0
Other assets	257	2,174
Restricted cash, net of current portion	0	5,000
Total Assets	56,133	77,893
Current Liabilities:
Accounts payable	2,400	2,121
Accrued and other liabilities	4,260	6,524
Long-term debt, current portion	9,887	8,796
Operating lease liabilities, current portion	1,142	1,068
Total current liabilities	17,689	18,509
Long-term debt, net of current portion	0	5,007
Deferred revenue, net of current portion	1,093	1,151
Operating lease liabilities, net of current portion	3,359	3,750
Liability related to the sale of future royalties	0	85,288
Other long-term liabilities	849	81
Total liabilities	22,990	113,786
Commitments and Contingencies (Note 10)
Stockholders’ Equity (Deficit):
Common stock, $0.001 par value—200,000,000 shares authorized as of June 30, 2022 and December 31, 2021; 147,331,963 and 136,819,647 shares issued and outstanding as of June 30, 2022 and December 31, 2021, respectively	147	137
Additional paid-in capital	444,591	437,554
Accumulated deficit	(411,595)	(473,584)
Total stockholders’ equity (deficit)	33,143	(35,893)
Total Liabilities and Stockholders’ Equity (Deficit)	$ 56,133	$ 77,893
[1]The condensed consolidated balance sheet as of December 31, 2021 has been derived from the audited financial statements as of that date included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021.

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Jun. 30, 2022	Dec. 31, 2021	[1]
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	200,000,000	200,000,000
Common stock, shares issued (in shares)	147,331,963	136,819,647
Common stock, shares outstanding (in shares)	147,331,963	136,819,647
[1]The condensed consolidated balance sheet as of December 31, 2021 has been derived from the audited financial statements as of that date included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021.

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Revenue:
Revenue	$ 570	$ 443	$ 1,012	$ 954
Operating costs and expenses:
Cost of goods sold	876	1,040	1,660	2,080
Research and development	1,544	724	2,859	1,693
Selling, general and administrative	6,822	8,694	14,160	16,338
Impairment of property and equipment	4,901	0	4,901	0
Total operating costs and expenses	14,143	10,458	23,580	20,111
Income (loss) from operations	(13,573)	(10,015)	(22,568)	(19,157)
Other income:
Interest expense	(327)	(614)	(717)	(1,286)
Interest income and other (expense) income, net	51	(16)	89	60
Non-cash interest income on liability related to the sale of future royalties	463	799	1,136	1,581
Gain on extinguishment of liability related to the sale of future royalties	84,052	0	84,052	0
Total other income	84,239	169	84,560	355
Net income (loss) before income taxes	70,666	(9,846)	61,992	(18,802)
Provision for income taxes	(3)	(5)	(3)	(5)
Net income (loss)	$ 70,663	$ (9,851)	$ 61,989	$ (18,807)
Net income (loss) per share of common stock, basic (in dollars per share)	$ 0.48	$ (0.08)	$ 0.42	$ (0.16)
Shares used in computing net income (loss) per share of common stock, basic – See Note 13 (in shares)	147,139,032	119,120,040	146,385,577	116,204,492
Net income (loss) per share of common stock, diluted (in dollars per share)	$ 0.48	$ (0.08)	$ 0.42	$ (0.16)
Shares used in computing net income (loss) per share of common stock, diluted – See Note 13 (in shares)	147,209,065	119,120,040	146,420,437	116,204,492
Product [Member]
Revenue:
Revenue	$ 570	$ 392	$ 1,012	$ 843
Contract and Other Collaboration [Member]
Revenue:
Revenue	$ 0	$ 51	$ 0	$ 111

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2020	98,812,008
Balance at Dec. 31, 2020	$ 98	$ 382,637	$ (438,485)	$ (55,750)
Stock-based compensation	$ 0	1,089	0	1,089
Issuance of common stock upon vesting of restricted stock units (in shares)	404,172
Issuance of common stock upon vesting of restricted stock units	$ 0	(249)	0	(249)
Issuance of common stock upon ESPP purchase (in shares)	183,132
Issuance of common stock upon ESPP purchase	$ 0	192	0	192
Net income (loss)	$ 0	0	(8,956)	(8,956)
Net proceeds from issuance of common stock in connection with equity financings (in shares)	19,701,562
Net proceeds from issuance of common stock in connection with equity financings	$ 20	36,340	0	36,360
Issuance of common stock upon exercise of stock options (in shares)	2,125
Issuance of common stock upon exercise of stock options	$ 0	2	0	2
Balance (in shares) at Mar. 31, 2021	119,102,999
Balance at Mar. 31, 2021	$ 118	420,011	(447,441)	(27,312)
Balance (in shares) at Dec. 31, 2020	98,812,008
Balance at Dec. 31, 2020	$ 98	382,637	(438,485)	(55,750)
Net income (loss)				(18,807)
Balance (in shares) at Jun. 30, 2021	119,179,806
Balance at Jun. 30, 2021	$ 119	421,184	(457,292)	(35,989)
Balance (in shares) at Mar. 31, 2021	119,102,999
Balance at Mar. 31, 2021	$ 118	420,011	(447,441)	(27,312)
Stock-based compensation	$ 0	1,172	0	1,172
Issuance of common stock upon vesting of restricted stock units (in shares)	74,438
Issuance of common stock upon vesting of restricted stock units	$ 0	0	0	0
Net income (loss)	$ 0	0	(9,851)	(9,851)
Issuance of common stock upon exercise of stock options (in shares)	2,369
Issuance of common stock upon exercise of stock options	$ 1	1	0	2
Balance (in shares) at Jun. 30, 2021	119,179,806
Balance at Jun. 30, 2021	$ 119	421,184	(457,292)	(35,989)
Balance (in shares) at Dec. 31, 2021	136,819,647
Balance at Dec. 31, 2021	$ 137	437,554	(473,584)	(35,893)	[1]
Stock-based compensation	$ 0	783	0	783
Issuance of common stock upon vesting of restricted stock units (in shares)	515,393
Issuance of common stock upon vesting of restricted stock units	$ 0	(58)	0	(58)
Issuance of common stock in connection with asset acquisition (in shares)	9,620,532
Issuance of common stock in connection with asset acquisition	$ 10	5,501	0	5,511
Issuance of common stock upon ESPP purchase (in shares)	153,435
Issuance of common stock upon ESPP purchase	$ 0	58	0	58
Net income (loss)	$ 0	0	(8,674)	(8,674)
Balance (in shares) at Mar. 31, 2022	147,109,007
Balance at Mar. 31, 2022	$ 147	443,838	(482,258)	(38,273)
Balance (in shares) at Dec. 31, 2021	136,819,647
Balance at Dec. 31, 2021	$ 137	437,554	(473,584)	(35,893)	[1]
Net income (loss)				$ 61,989
Issuance of common stock upon exercise of stock options (in shares)				0
Balance (in shares) at Jun. 30, 2022	147,331,963
Balance at Jun. 30, 2022	$ 147	444,591	(411,595)	$ 33,143
Balance (in shares) at Mar. 31, 2022	147,109,007
Balance at Mar. 31, 2022	$ 147	443,838	(482,258)	(38,273)
Stock-based compensation	$ 0	753	0	753
Issuance of common stock upon vesting of restricted stock units (in shares)	222,956
Issuance of common stock upon vesting of restricted stock units	$ 0	0	0	0
Net income (loss)	$ 0	0	70,663	70,663
Balance (in shares) at Jun. 30, 2022	147,331,963
Balance at Jun. 30, 2022	$ 147	$ 444,591	$ (411,595)	$ 33,143
[1]The condensed consolidated balance sheet as of December 31, 2021 has been derived from the audited financial statements as of that date included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021.

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Cash flows from operating activities:
Net income (loss)	$ 61,989	$ (18,807)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Non-cash royalty revenue related to royalty monetization	0	(83)
Non-cash interest income on liability related to royalty monetization	(1,136)	(1,581)
Depreciation and amortization	881	1,029
Non-cash interest expense related to debt financing	250	430
Stock-based compensation	1,536	2,261
Non-cash gain on termination of liability related to royalty monetization	(84,152)	0
Impairment of property and equipment	4,901	0
Other	(7)	(61)
Changes in operating assets and liabilities:
Accounts receivable	(204)	531
Inventories	201	143
Prepaid expenses and other assets	(212)	(277)
Accounts payable	286	(65)
Accrued liabilities	(1,582)	(963)
Operating lease liabilities	(402)	(563)
Deferred revenue	(29)	(49)
Net cash used in operating activities	(17,680)	(18,055)
Cash flows from investing activities:
Purchase of property and equipment	(158)	(1,615)
Purchase of investments	(7,369)	(38,201)
Cash paid for asset acquisition, net of cash acquired	(1,687)	0
Proceeds from maturities of investments	38,562	24,784
Net cash provided by (used in) investing activities	29,348	(15,032)
Cash flows from financing activities:
Payment of long-term debt	(4,166)	(4,167)
Net proceeds from issuance of common stock in connection with equity financings	0	36,360
Net proceeds from issuance of common stock through equity plans	58	196
Payment of employee tax obligations related to vesting of restricted stock units	(58)	(249)
Net cash (used in) provided by financing activities	(4,166)	32,140
Net increase in cash, cash equivalents and restricted cash	7,502	(947)
Cash, cash equivalents and restricted cash—Beginning of period (See reconciliation in Note 1)	12,663	27,274
Cash, cash equivalents and restricted cash—End of period (See reconciliation in Note 1)	20,165	26,327
NONCASH INVESTING ACTIVITIES:
Purchases of property and equipment in accounts payable and accrued liabilities	1,464	839
Liability for held back shares in connection with asset acquisition in other long-term liabilities	800	0
Issuance of common stock in connection with asset acquisition	5,511	0
Establishment of right-of-use asset and lease liability	$ 85	$ 0

Note 1 - Organization and Summa

Note 1 - Organization and Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
Basis of Presentation and Significant Accounting Policies [Text Block]	1. The Company AcelRx Pharmaceuticals, Inc., or the Company, or AcelRx, was incorporated in Delaware on July 13, 2005 AcelRx is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. DSUVIA® November 2, 2018, first 2019. June 2018, not may one July 2021, May 12, 2021 ( Termination of Gr nenthal Agreements July 2022, July 2021, 10 3 10 50 January 7, 2022, November 14, 2021, 4. not second 608, Termination of Gr nenthal Agreements On December 16, 2013, July 17, 2015 September 20, 2016, 28 September 2015, December 16, 2013, July 22, 2015, July 17, 2015. On May 18, 2020, November 13, 2020. May 12, 2021 May 12, 2021. July 2022, Termination of Royalty Monetization On September 18, 2015, August 31, 2020, May 31, 2022, May 31, 2022, no Liquidity and Going Concern The Condensed Consolidated Financial Statements for the three six June 30, 2022 three six June 30, 2022; twelve one 10 may SM third not may not not may third may may not Principles of Consolidation The Condensed Consolidated Financial Statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. Basis of Presentation The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and the rules and regulations of the United States Securities and Exchange Commission, or SEC. Accordingly, they do not Operating results for the three six June 30, 2022, not may December 31, 2022, December 31, 2021, December 31, 2021, 10 March 10, 2022. 10 December 31, 2021, Reclassifications Certain prior year amounts in the Consolidated Financial Statements have been reclassified to conform to the current year's presentation. In particular, the restricted cash classified as “Cash and cash equivalents” has been reclassified to “Restricted cash, net of current portion” in the Condensed Consolidated Balance Sheets as of December 31, 2021 December 31, 2021, June 30, 2021 December 31, 2020. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the Consolidated Financial Statements and accompanying notes. Management evaluates its estimates on an ongoing basis including critical accounting policies. Estimates are based on historical experience and on various other market-specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not Cash, Cash Equivalents and Restricted Cash The Company considers all highly liquid investments with an original maturity (at date of purchase) of three On May 30, 2019, not June 30, 2022, The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the Condensed Consolidated Balance Sheets that sum to the total of the same such amounts in the Condensed Consolidated Statement of Cash Flows: Balance as of June 30, 2022 December 31, 2021 Cash and cash equivalents $ 15,165 $ 7,663 Restricted cash 5,000 — Restricted cash, net of current portion — 5,000 Total cash, cash equivalents, and restricted cash $ 20,165 $ 12,663 Balance as of June 30, 2021 December 31, 2020 Cash and cash equivalents $ 21,327 $ 22,274 Restricted cash, net of current portion 5,000 5,000 Total cash, cash equivalents, and restricted cash $ 26,327 $ 27,274 Restructuring Costs The Company's restructuring costs consist of employee termination benefit costs. Liabilities for costs associated with the cost reduction plan are recognized when the liability is incurred and are measured at fair value. One-time termination benefits are expensed at the date the Company notifies the employee, unless the employee must provide future service, in which case the benefits are expensed ratably over the future service period. In May 2022, three June 30, 2022, June 30, 2022. second 2022. No Significant Accounting Policies The Company’s significant accounting policies are detailed in its Annual Report on Form 10 December 31, 2021. no six June 30, 2022, 2021 10 Acquisitions The Company evaluates acquisitions of assets and other similar transactions to assess whether or not first not, not Acquisitions meeting the definition of business combinations are accounted for using the acquisition method of accounting, which requires that the purchase price be allocated to the net assets acquired at their respective fair values. In a business combination, any excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill. For asset acquisitions, a cost accumulation model is used to determine the cost of an asset acquisition. Direct transaction costs are recognized as part of the cost of an asset acquisition. The Company also evaluates which elements of a transaction should be accounted for as a part of an asset acquisition and which should be accounted for separately. The cost of an asset acquisition, including transaction costs, is allocated to identifiable assets acquired and liabilities assumed based on a relative fair value basis. Goodwill is not not no may not Recently Issued Accounting Pronouncements In June 2016, 2016 13, Financial Instruments Credit Losses: Measurement of Credit Losses on Financial Instruments, 2016 13. 2016 13 2016 13 January 1, 2023, January 1, 2020. May 2019, 2019 05, Financial Instruments Credit Losses, 2019 05, 2016 13. 2016 13 2019 05 not In March 2020, 2020 04, Reference Rate Reform (Topic 848 may December 31, 2022. January 2021, 2021 01, Reference Rate Reform (Topic 848 848 2020 04.

Note 2 - Investments and Fair V

Note 2 - Investments and Fair Value Measurement	6 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
Investments and Fair Value Measurement Disclosure [Text Block]	2. Investments The Company classifies its marketable securities as available-for-sale and records its investments at fair value. Available-for-sale securities are carried at estimated fair value based on quoted market prices or observable market inputs of almost identical assets, with the unrealized holding gains and losses included in accumulated other comprehensive income (loss). Marketable securities which have maturities beyond one The table below summarizes the Company’s cash, cash equivalents, restricted cash and short-term investments (in thousands): As of June 30, 2022 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Cash, cash equivalents and restricted cash: Cash $ 2,637 $ — $ — $ 2,637 Money market funds 1,150 — — 1,150 Commercial paper 16,378 — — 16,378 Total cash, cash equivalents and restricted cash 20,165 — — 20,165 Short-term investments: Commercial paper 7,758 — — 7,758 Total short-term investments 7,758 — — 7,758 Total cash, cash equivalents, restricted cash and short-term investments $ 27,923 $ — $ — $ 27,923 As of December 31, 2021 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Cash, cash equivalents and restricted cash: Cash $ 1,443 $ — $ — $ 1,443 Money market funds 2,822 — — 2,822 Commercial paper 8,398 — — 8,398 Total cash, cash equivalents and restricted cash 12,663 — — 12,663 Short-term investments: Commercial paper 29,504 — — 29,504 Corporate debt securities 9,463 — — 9,463 Total short-term investments 38,967 — — 38,967 Total cash, cash equivalents, restricted cash and short-term investments $ 51,630 $ — $ — $ 51,630 There were no other-than-temporary impairments for these securities at June 30, 2022 December 31, 2021. no three six June 30, 2022 2021. As of June 30, 2022, December 31, 2021, one Fair Value Measurement The Company’s financial instruments consist of Level I and II assets and Level III liabilities. Money market funds are highly liquid investments and are actively traded. The pricing information on these investment instruments are readily available and can be independently validated as of the measurement date. This approach results in the classification of these securities as Level 1 third June 30, 2022, December 31, 2021, two The following table sets forth the fair value of the Company’s financial assets and liabilities by level within the fair value hierarchy (in thousands): As of June 30, 2022 Fair Value Level I Level II Level III Assets Money market funds $ 1,150 $ 1,150 $ — $ — Commercial paper 24,136 — 24,136 — Total assets measured at fair value $ 25,286 $ 1,150 $ 24,136 $ — Liabilities Contingent put option liability $ 49 $ — $ — $ 49 Total liabilities measured at fair value $ 49 $ — $ — $ 49 As of December 31, 2021 Assets Fair Value Level I Level II Level III Money market funds $ 2,822 $ 2,822 $ — $ — Commercial paper 37,902 — 37,902 — Corporate debt securities 9,463 — 9,463 — Total assets measured at fair value $ 50,187 $ 2,822 $ 47,365 $ — Liabilities Contingent put option liability $ 81 $ — $ — $ 81 Total liabilities measured at fair value $ 81 $ — $ — $ 81 The following tables set forth a summary of the changes in the fair value of the Company’s Level III financial liabilities for the three six June 30, 2022 2021 Three Months Ended June 30, 2022 Six Months Ended June 30, 2022 Fair value—beginning of period $ 55 $ 81 Change in fair value of contingent put option associated with the Loan Agreement (6 ) (32 ) Fair value—end of period $ 49 $ 49 Three Months Ended June 30, 2021 Six Months Ended June 30, 2021 Fair value—beginning of period $ 181 $ 246 Change in fair value of contingent put option associated with the Loan Agreement (53 ) (118 ) Fair value—end of period $ 128 $ 128 There were no transfers between Level I, Level II or Level III of the fair value hierarchy during the three six June 30, 2022 2021.

Note 3 - Inventories, Net

Note 3 - Inventories, Net	6 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
Inventory Disclosure [Text Block]	3. Inventories consist of raw materials, work in process and finished goods and are stated at the lower of cost or net realizable value and consist of the following (in thousands): Balance as of June 30, 2022 December 31, 2021 Raw materials $ 680 $ 722 Work-in-process — 159 Finished goods 221 230 Total $ 901 $ 1,111 The Company did not three six June 30, 2022. three six June 30, 2021,

Note 4 - Asset Acquisition

Note 4 - Asset Acquisition	6 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
Business Combination Disclosure [Text Block]	4. On January 7, 2022, five January 7, 2022, The shares issued pursuant to the Merger Agreement were issued in private placements pursuant to the exemption from registration under Section 4 2 1933, 506 not The Merger Agreement has been accounted for as an asset acquisition of a single IPR&D asset that has an alternative future use. The initial measurement of the asset purchased of $8.8 million was based on the purchase cost of $12.4 million including (i) $6.0 million common stock fair value on the closing date (issued and held back on the acquisition date), (ii) $0.5 million seller’s costs paid by the Company, (iii) $3.5 million cash and (iv) approximately $2.5 million of transaction costs less purchase price allocated to cash acquired of $3.5 million. Due to the nature of regulatory and sales-based milestones, the contingent consideration of up to $26.0 million was not not June 30, 2022, none The following table summarizes the total consideration for the acquisition and the value of the IPR&D asset acquired (in thousands): Consideration Cash $ 3,536 Issuance of common stock to Lowell security holders in connection with asset acquisition 5,161 Issuance of common stock to settle Lowell’s transaction costs in connection with asset acquisition 350 Liability for issuance of 1,396,526 (1) 800 Transaction costs 2,521 Total consideration $ 12,368 IPR&D Asset Acquired Purchase price $ 12,368 Cash acquired (3,549 ) Total IPR&D asset acquired (2) $ 8,819 ( 1 ( 2 The IPR&D asset will be treated initially as an indefinite-lived asset, and as a long-lived asset, it will be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not three six June 30, 2022.

Note 5 - Property and Equipment

Note 5 - Property and Equipment, Net	6 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	5. Property and equipment, net consist of the following (in thousands): Balance as of June 30, 2022 December 31, 2021 Laboratory equipment $ 4,406 $ 4,406 Leasehold improvements 5,838 5,838 Computer equipment and software 1,589 1,589 Construction in process 9,459 13,805 Tooling 826 826 Furniture and fixtures 250 250 22,368 26,714 Less accumulated depreciation and amortization (11,293 ) (10,786 ) Property and equipment, net $ 11,075 $ 15,928 As of June 30, 2022, not not July 2022, not no three six June 30, 2022. three six June 30, 2022, three six June 30, 2022,

Note 6 - Revenue From Contracts

Note 6 - Revenue From Contracts With Customers	6 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	6. The following table summarizes revenue from contracts with customers for the three six June 30, 2022 2021 Three months ended June 30, 2022 Six months ended June 30, 2022 Product sales: DSUVIA $ 444 $ 886 DZUVEO 1 126 126 Total product sales $ 570 $ 1,012 1 third 2022. Three months ended June 30, 2021 Six months ended June 30, 2021 Product sales: DSUVIA $ 392 $ 573 Zalviso — 270 Total product sales 392 843 Contract and collaboration revenue: Non-cash royalty revenue related to Royalty Monetization (Note 9) 38 83 Royalty revenue 13 28 Total revenues from contract and other collaboration 51 111 Total revenue $ 443 $ 954 For additional details on the Company’s accounting policy regarding revenue recognition, refer to Note 1 10 December 31, 2021. Product Sales The Company’s commercial launch of DSUVIA in the United States occurred in the first 2019. May 12, 2021, July 2022, not June 30, 2022. Contract and Other Collaboration Contract and other collaboration revenue includes revenue under the Grünenthal Agreements related to research and development services, non-cash royalty revenue related to the Royalty Monetization and royalty revenue for sales of Zalviso in Europe and license revenue recognized under the DZUVEO Agreement. For the three six June 30, 2022, not Contract Liabilities A contract liability of $1.2 million was recorded on the Condensed Consolidated Balance Sheets as deferred revenue as of June 30, 2022, not The following table presents changes in the Company’s contract liability for the six June 30, 2022 2021 Balance at January 1, 2022 $ 1,237 Deductions for performance obligations satisfied: In current period (29 ) Balance at June 30, 2022 $ 1,208 Balance at January 1, 2021 $ 49 Deductions for performance obligations satisfied: In current period (49 ) Balance at June 30, 2021 $ —

Note 7 - Long-term Debt

Note 7 - Long-term Debt	6 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
Long-Term Debt [Text Block]	7. Loan Agreement with Oxford On May 30, 2019, May 30, 2019. not In connection with the Loan Agreement, on May 30, 2019, As of June 30, 2022 December 31, 2021, three six June 30, 2022, three six June 30, 2021, Non-Interest Bearing Payments for the Construction of Leasehold Improvements In August 2019, may four July 2022. June 30, 2022 December 31, 2021, June 30, 2022

Note 8 - Leases

Note 8 - Leases	6 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	8. Office Lease On March 26, 2021, 25821 April 1, 2021. two three one Contract Manufacturing Leases The Company has entered into commercial supply manufacturing services agreements related to Zalviso and DSUVIA containing fixed fees which it has determined are in-substance lease payments. For additional information on these agreements, refer to Note 9 10 December 31, 2021. The components of lease expense are presented in the following table (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Operating lease costs $ 343 $ 440 $ 686 $ 780 Gain on derecognition of operating lease — — — (522 ) Sublease income — (50 ) — (199 ) Loss on termination of sublease — 331 — 331 Net lease costs $ 343 $ 721 $ 686 $ 390 The weighted average remaining lease term and discount rate related to the operating leases are presented in the following table: June 30, 2022 June 30, 2021 Weighted-average remaining lease term – operating leases (years) 4.57 5.41 Weighted-average remaining discount rate – operating leases 12.8 % 12.8 % Maturities of lease liabilities as of June 30, 2022 Year: 2022 (remaining six months) $ 921 2023 1,344 2024 1,040 2025 1,040 2026 1,040 Thereafter 415 Total future minimum lease payments 5,800 Less imputed interest (1,299 ) Total $ 4,501 Reported as: Operating lease liabilities $ 4,501 Operating lease liabilities, current portion (1,142 ) Operating lease liabilities, net of current portion $ 3,359

Note 9 - Liability Related to S

Note 9 - Liability Related to Sale of Future Royalties	6 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
Liability Related To Sale Of Future Royalties Disclosure [Text Block]	9. On September 18, 2015, first four 80% $195.0 The Company periodically assessed the expected royalty and milestone payments using a combination of historical results, internal projections and forecasts from external sources. To the extent such payments were greater or less than the Company’s initial estimates or the timing of such payments is materially different than its original estimates, the Company prospectively adjusted the amortization of the liability and the effective interest rate. During the three June 30, 2020, November 13, 2020. August 31, 2020, May 12, 2021 May 12, 2021. On May 31, 2022, May 31, 2022, no The effective interest income rate for each of the three six June 30, 2022, three six June 30, 2021, The following table shows the activity within the liability account related to the sale of future royalties for the six June 30, 2022 September 18, 2015 June 30, 2022 ( Six months ended June 30, 2022 Period from inception to June 30, 2022 Liability related to sale of future royalties — beginning balance $ 85,288 $ — Proceeds from sale of future royalties — 61,184 Non-cash royalty revenue — (1,083 ) Non-cash interest (income) expense recognized (1,136 ) 24,051 Consideration paid for termination of Royalty Monetization (100 ) (100 ) Gain on termination of liability related to sale of future royalties (84,052 ) (84,052 ) Liability related to sale of future royalties as of June 30, 2022 $ — $ — As mentioned above, the Royalty Monetization was terminated on May 31, 2022.

Note 10 - Commitments and Conti

Note 10 - Commitments and Contingencies	6 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	10. Litigation On June 8, 2021, 10 20 10b 5 December 16, 2021, March 7, 2022. three 10 20 10b 5 20A May 6, 2022, July 21, 2022. September 1, 2022. On July 6, 2021, September 30, 2021, October 26, 2021, November 17, 2021, three nine four December 6, 2021, four 1A. may . The Company believes that these lawsuits are without merit and intends to vigorously defend against them. Given the uncertainty of litigation, the preliminary stage of the cases, and the legal standards that must be met for, among other things, class certification and success on the merits, the Company cannot estimate the reasonably possible loss or range of loss that may

Note 11 - Stockholders' Equity

Note 11 - Stockholders' Equity	6 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	11. Equity Common Stock ATM Agreement The Company has entered into the ATM Agreement with Cantor, as agent, pursuant to which the Company may The Company did not three six June 30, 2022. three six June 30, 2021, June 30, 2022, may

Note 12 - Stock-based Compensat

Note 12 - Stock-based Compensation	6 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
Share-Based Payment Arrangement [Text Block]	12. The Company recorded total stock-based compensation expense for stock options, restricted stock units, or RSUs, and the Amended and Restated 2011 Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Cost of goods sold $ 16 $ 21 $ 35 $ 43 Research and development 153 200 327 381 Selling, general and administrative 584 951 1,174 1,837 Total $ 753 $ 1,172 $ 1,536 $ 2,261 The following table summarizes restricted stock unit activity under the Company’s equity incentive plans: Weighted Number of Average Restricted Grant Date Stock Units Fair Value Restricted stock units outstanding, January 1, 2022 1,774,376 $ 1.71 Granted 1,061,826 0.40 Vested (880,315 ) 1.78 Forfeited (313,288 ) 1.29 Restricted stock units outstanding, June 30, 2022 1,642,599 $ 0.91 Upon vesting, certain of the Company’s RSUs may three six June 30, 2022, The following table summarizes stock option activity under the Company’s equity incentive plans: Number of Stock Options Outstanding Weighted- Average Exercise Price Weighted- Average Remaining Contractual Life (Years) Aggregate Intrinsic Value (in thousands) January 1, 2022 14,284,050 $ 2.99 Granted 2,123,650 0.40 Forfeited (552,745 ) 1.37 Expired (812,693 ) 3.31 Exercised — — June 30, 2022 15,042,262 $ 2.67 5.8 $ — Vested and exercisable options—June 30, 2022 10,473,947 $ 3.31 4.5 $ — Vested and expected to vest—June 30, 2022 15,042,262 $ 2.67 5.8 $ — The per-share weighted average grant date fair value of the options granted for the six June 30, 2022 Six months ended June 30, 2022 Expected term (in years) 6.3 Risk-free interest rate 1.6% - 2.2% Expected volatility 88% Expected dividend rate 0% As of June 30, 2022,

Note 13 - Net Income (Loss) Per

Note 13 - Net Income (Loss) Per Share of Common Stock	6 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
Earnings Per Share [Text Block]	13. The Company’s basic net income (loss) per share of common stock is calculated by dividing the net income (loss) by the weighted average number of shares of common stock outstanding for the period. The diluted net income (loss) per share of common stock is computed by giving effect to all potential common stock equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, options to purchase common stock, RSUs, and warrants to purchase common stock were considered to be common stock equivalents. In periods with a reported net loss, common stock equivalents are excluded from the calculation of diluted net loss per share of common stock if their effect is antidilutive. The following table sets forth the computation of the Company’s basic and diluted net income (loss) per share of common stock during the three six June 30, 2022 2021 Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 (in thousands, except share and per share amounts) Numerator: Net income (loss) $ 70,663 $ (9,851 ) $ 61,989 $ (18,807 ) Denominator: Weighted average shares outstanding — basic 147,139,032 119,120,040 146,385,577 116,204,492 Dilutive effect of RSUs 70,033 — 34,860 — Weighted average shares outstanding — diluted 147,209,065 119,120,040 146,420,437 116,204,492 Net income (loss) per share — basic $ 0.48 $ (0.08 ) $ 0.42 $ (0.16 ) Net income (loss) per share — diluted $ 0.48 $ (0.08 ) $ 0.42 $ (0.16 ) The following outstanding shares of common stock equivalents were excluded from the computation of diluted net income (loss) per share of common stock for the periods presented because including them would have been antidilutive: Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 RSUs, stock options and ESPP to purchase common stock 16,520,200 16,907,412 16,463,459 16,907,412 Common stock warrants 17,676,679 176,679 17,676,679 176,679 In addition, the shares held back and contingently issuable in connection with the Lowell Merger, as described in Note 4. not

Note 14 - Subsequent Event

Note 14 - Subsequent Event	6 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
Subsequent Events [Text Block]	14. On August 3, 2022, August 3, 2022, February 3, 2028.

Significant Accounting Policies

Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Business Description of Entity [Policy Text Block]	The Company AcelRx Pharmaceuticals, Inc., or the Company, or AcelRx, was incorporated in Delaware on July 13, 2005 AcelRx is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. DSUVIA® November 2, 2018, first 2019. June 2018, not may one July 2021, May 12, 2021 ( Termination of Gr nenthal Agreements July 2022, July 2021, 10 3 10 50 January 7, 2022, November 14, 2021, 4. not second 608, Termination of Gr nenthal Agreements On December 16, 2013, July 17, 2015 September 20, 2016, 28 September 2015, December 16, 2013, July 22, 2015, July 17, 2015. On May 18, 2020, November 13, 2020. May 12, 2021 May 12, 2021. July 2022, Termination of Royalty Monetization On September 18, 2015, August 31, 2020, May 31, 2022, May 31, 2022, no Liquidity and Going Concern The Condensed Consolidated Financial Statements for the three six June 30, 2022 three six June 30, 2022; twelve one 10 may SM third not may not not may third may may not
Consolidation, Policy [Policy Text Block]	Principles of Consolidation The Condensed Consolidated Financial Statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and the rules and regulations of the United States Securities and Exchange Commission, or SEC. Accordingly, they do not Operating results for the three six June 30, 2022, not may December 31, 2022, December 31, 2021, December 31, 2021, 10 March 10, 2022. 10 December 31, 2021,
Reclassification, Comparability Adjustment [Policy Text Block]	Reclassifications Certain prior year amounts in the Consolidated Financial Statements have been reclassified to conform to the current year's presentation. In particular, the restricted cash classified as “Cash and cash equivalents” has been reclassified to “Restricted cash, net of current portion” in the Condensed Consolidated Balance Sheets as of December 31, 2021 December 31, 2021, June 30, 2021 December 31, 2020.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the Consolidated Financial Statements and accompanying notes. Management evaluates its estimates on an ongoing basis including critical accounting policies. Estimates are based on historical experience and on various other market-specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash, Cash Equivalents and Restricted Cash The Company considers all highly liquid investments with an original maturity (at date of purchase) of three On May 30, 2019, not June 30, 2022, The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the Condensed Consolidated Balance Sheets that sum to the total of the same such amounts in the Condensed Consolidated Statement of Cash Flows: Balance as of June 30, 2022 December 31, 2021 Cash and cash equivalents $ 15,165 $ 7,663 Restricted cash 5,000 — Restricted cash, net of current portion — 5,000 Total cash, cash equivalents, and restricted cash $ 20,165 $ 12,663 Balance as of June 30, 2021 December 31, 2020 Cash and cash equivalents $ 21,327 $ 22,274 Restricted cash, net of current portion 5,000 5,000 Total cash, cash equivalents, and restricted cash $ 26,327 $ 27,274
Costs Associated with Exit or Disposal Activities or Restructurings, Policy [Policy Text Block]	Restructuring Costs The Company's restructuring costs consist of employee termination benefit costs. Liabilities for costs associated with the cost reduction plan are recognized when the liability is incurred and are measured at fair value. One-time termination benefits are expensed at the date the Company notifies the employee, unless the employee must provide future service, in which case the benefits are expensed ratably over the future service period. In May 2022, three June 30, 2022, June 30, 2022. second 2022. No
Business Combinations Policy [Policy Text Block]	Acquisitions The Company evaluates acquisitions of assets and other similar transactions to assess whether or not first not, not Acquisitions meeting the definition of business combinations are accounted for using the acquisition method of accounting, which requires that the purchase price be allocated to the net assets acquired at their respective fair values. In a business combination, any excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill. For asset acquisitions, a cost accumulation model is used to determine the cost of an asset acquisition. Direct transaction costs are recognized as part of the cost of an asset acquisition. The Company also evaluates which elements of a transaction should be accounted for as a part of an asset acquisition and which should be accounted for separately. The cost of an asset acquisition, including transaction costs, is allocated to identifiable assets acquired and liabilities assumed based on a relative fair value basis. Goodwill is not not no may not
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Issued Accounting Pronouncements In June 2016, 2016 13, Financial Instruments Credit Losses: Measurement of Credit Losses on Financial Instruments, 2016 13. 2016 13 2016 13 January 1, 2023, January 1, 2020. May 2019, 2019 05, Financial Instruments Credit Losses, 2019 05, 2016 13. 2016 13 2019 05 not In March 2020, 2020 04, Reference Rate Reform (Topic 848 may December 31, 2022. January 2021, 2021 01, Reference Rate Reform (Topic 848 848 2020 04.

Note 1 - Organization and Sum_2

Note 1 - Organization and Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2022
Notes Tables
Schedule of Cash and Cash Equivalents [Table Text Block]	Balance as of June 30, 2022 December 31, 2021 Cash and cash equivalents $ 15,165 $ 7,663 Restricted cash 5,000 — Restricted cash, net of current portion — 5,000 Total cash, cash equivalents, and restricted cash $ 20,165 $ 12,663 Balance as of June 30, 2021 December 31, 2020 Cash and cash equivalents $ 21,327 $ 22,274 Restricted cash, net of current portion 5,000 5,000 Total cash, cash equivalents, and restricted cash $ 26,327 $ 27,274

Note 2 - Investments and Fair_2

Note 2 - Investments and Fair Value Measurement (Tables)	6 Months Ended
	Jun. 30, 2022
Notes Tables
Cash, Cash Equivalents and Investments [Table Text Block]	As of June 30, 2022 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Cash, cash equivalents and restricted cash: Cash $ 2,637 $ — $ — $ 2,637 Money market funds 1,150 — — 1,150 Commercial paper 16,378 — — 16,378 Total cash, cash equivalents and restricted cash 20,165 — — 20,165 Short-term investments: Commercial paper 7,758 — — 7,758 Total short-term investments 7,758 — — 7,758 Total cash, cash equivalents, restricted cash and short-term investments $ 27,923 $ — $ — $ 27,923 As of December 31, 2021 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Cash, cash equivalents and restricted cash: Cash $ 1,443 $ — $ — $ 1,443 Money market funds 2,822 — — 2,822 Commercial paper 8,398 — — 8,398 Total cash, cash equivalents and restricted cash 12,663 — — 12,663 Short-term investments: Commercial paper 29,504 — — 29,504 Corporate debt securities 9,463 — — 9,463 Total short-term investments 38,967 — — 38,967 Total cash, cash equivalents, restricted cash and short-term investments $ 51,630 $ — $ — $ 51,630
Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]	As of June 30, 2022 Fair Value Level I Level II Level III Assets Money market funds $ 1,150 $ 1,150 $ — $ — Commercial paper 24,136 — 24,136 — Total assets measured at fair value $ 25,286 $ 1,150 $ 24,136 $ — Liabilities Contingent put option liability $ 49 $ — $ — $ 49 Total liabilities measured at fair value $ 49 $ — $ — $ 49 As of December 31, 2021 Assets Fair Value Level I Level II Level III Money market funds $ 2,822 $ 2,822 $ — $ — Commercial paper 37,902 — 37,902 — Corporate debt securities 9,463 — 9,463 — Total assets measured at fair value $ 50,187 $ 2,822 $ 47,365 $ — Liabilities Contingent put option liability $ 81 $ — $ — $ 81 Total liabilities measured at fair value $ 81 $ — $ — $ 81
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	Three Months Ended June 30, 2022 Six Months Ended June 30, 2022 Fair value—beginning of period $ 55 $ 81 Change in fair value of contingent put option associated with the Loan Agreement (6 ) (32 ) Fair value—end of period $ 49 $ 49 Three Months Ended June 30, 2021 Six Months Ended June 30, 2021 Fair value—beginning of period $ 181 $ 246 Change in fair value of contingent put option associated with the Loan Agreement (53 ) (118 ) Fair value—end of period $ 128 $ 128

Note 3 - Inventories, Net (Tabl

Note 3 - Inventories, Net (Tables)	6 Months Ended
	Jun. 30, 2022
Notes Tables
Schedule of Inventory, Current [Table Text Block]	Balance as of June 30, 2022 December 31, 2021 Raw materials $ 680 $ 722 Work-in-process — 159 Finished goods 221 230 Total $ 901 $ 1,111

Note 4 - Asset Acquisition (Tab

Note 4 - Asset Acquisition (Tables)	6 Months Ended
	Jun. 30, 2022
Notes Tables
Schedule of Business Acquisitions, by Acquisition [Table Text Block]	Consideration Cash $ 3,536 Issuance of common stock to Lowell security holders in connection with asset acquisition 5,161 Issuance of common stock to settle Lowell’s transaction costs in connection with asset acquisition 350 Liability for issuance of 1,396,526 (1) 800 Transaction costs 2,521 Total consideration $ 12,368 IPR&D Asset Acquired Purchase price $ 12,368 Cash acquired (3,549 ) Total IPR&D asset acquired (2) $ 8,819

Note 5 - Property and Equipme_2

Note 5 - Property and Equipment, Net (Tables)	6 Months Ended
	Jun. 30, 2022
Notes Tables
Property, Plant and Equipment [Table Text Block]	Balance as of June 30, 2022 December 31, 2021 Laboratory equipment $ 4,406 $ 4,406 Leasehold improvements 5,838 5,838 Computer equipment and software 1,589 1,589 Construction in process 9,459 13,805 Tooling 826 826 Furniture and fixtures 250 250 22,368 26,714 Less accumulated depreciation and amortization (11,293 ) (10,786 ) Property and equipment, net $ 11,075 $ 15,928

Note 6 - Revenue From Contrac_2

Note 6 - Revenue From Contracts With Customers (Tables)	6 Months Ended
	Jun. 30, 2022
Notes Tables
Disaggregation of Revenue [Table Text Block]	Three months ended June 30, 2022 Six months ended June 30, 2022 Product sales: DSUVIA $ 444 $ 886 DZUVEO 1 126 126 Total product sales $ 570 $ 1,012 Three months ended June 30, 2021 Six months ended June 30, 2021 Product sales: DSUVIA $ 392 $ 573 Zalviso — 270 Total product sales 392 843 Contract and collaboration revenue: Non-cash royalty revenue related to Royalty Monetization (Note 9) 38 83 Royalty revenue 13 28 Total revenues from contract and other collaboration 51 111 Total revenue $ 443 $ 954
Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]	Balance at January 1, 2022 $ 1,237 Deductions for performance obligations satisfied: In current period (29 ) Balance at June 30, 2022 $ 1,208 Balance at January 1, 2021 $ 49 Deductions for performance obligations satisfied: In current period (49 ) Balance at June 30, 2021 $ —

Note 8 - Leases (Tables)

Note 8 - Leases (Tables)	6 Months Ended
	Jun. 30, 2022
Notes Tables
Lease, Cost [Table Text Block]	Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Operating lease costs $ 343 $ 440 $ 686 $ 780 Gain on derecognition of operating lease — — — (522 ) Sublease income — (50 ) — (199 ) Loss on termination of sublease — 331 — 331 Net lease costs $ 343 $ 721 $ 686 $ 390 June 30, 2022 June 30, 2021 Weighted-average remaining lease term – operating leases (years) 4.57 5.41 Weighted-average remaining discount rate – operating leases 12.8 % 12.8 %
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	Year: 2022 (remaining six months) $ 921 2023 1,344 2024 1,040 2025 1,040 2026 1,040 Thereafter 415 Total future minimum lease payments 5,800 Less imputed interest (1,299 ) Total $ 4,501 Reported as: Operating lease liabilities $ 4,501 Operating lease liabilities, current portion (1,142 ) Operating lease liabilities, net of current portion $ 3,359

Note 9 - Liability Related to_2

Note 9 - Liability Related to Sale of Future Royalties (Tables)	6 Months Ended
	Jun. 30, 2022
Notes Tables
Other Liabilities [Table Text Block]	Six months ended June 30, 2022 Period from inception to June 30, 2022 Liability related to sale of future royalties — beginning balance $ 85,288 $ — Proceeds from sale of future royalties — 61,184 Non-cash royalty revenue — (1,083 ) Non-cash interest (income) expense recognized (1,136 ) 24,051 Consideration paid for termination of Royalty Monetization (100 ) (100 ) Gain on termination of liability related to sale of future royalties (84,052 ) (84,052 ) Liability related to sale of future royalties as of June 30, 2022 $ — $ —

Note 12 - Stock-based Compens_2

Note 12 - Stock-based Compensation (Tables)	6 Months Ended
	Jun. 30, 2022
Notes Tables
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Cost of goods sold $ 16 $ 21 $ 35 $ 43 Research and development 153 200 327 381 Selling, general and administrative 584 951 1,174 1,837 Total $ 753 $ 1,172 $ 1,536 $ 2,261
Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]	Weighted Number of Average Restricted Grant Date Stock Units Fair Value Restricted stock units outstanding, January 1, 2022 1,774,376 $ 1.71 Granted 1,061,826 0.40 Vested (880,315 ) 1.78 Forfeited (313,288 ) 1.29 Restricted stock units outstanding, June 30, 2022 1,642,599 $ 0.91
Share-Based Payment Arrangement, Option, Activity [Table Text Block]	Number of Stock Options Outstanding Weighted- Average Exercise Price Weighted- Average Remaining Contractual Life (Years) Aggregate Intrinsic Value (in thousands) January 1, 2022 14,284,050 $ 2.99 Granted 2,123,650 0.40 Forfeited (552,745 ) 1.37 Expired (812,693 ) 3.31 Exercised — — June 30, 2022 15,042,262 $ 2.67 5.8 $ — Vested and exercisable options—June 30, 2022 10,473,947 $ 3.31 4.5 $ — Vested and expected to vest—June 30, 2022 15,042,262 $ 2.67 5.8 $ —
Performance Shares [Member]
Notes Tables
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Six months ended June 30, 2022 Expected term (in years) 6.3 Risk-free interest rate 1.6% - 2.2% Expected volatility 88% Expected dividend rate 0%

Note 13 - Net Income (Loss) P_2

Note 13 - Net Income (Loss) Per Share of Common Stock (Tables)	6 Months Ended
	Jun. 30, 2022
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 (in thousands, except share and per share amounts) Numerator: Net income (loss) $ 70,663 $ (9,851 ) $ 61,989 $ (18,807 ) Denominator: Weighted average shares outstanding — basic 147,139,032 119,120,040 146,385,577 116,204,492 Dilutive effect of RSUs 70,033 — 34,860 — Weighted average shares outstanding — diluted 147,209,065 119,120,040 146,420,437 116,204,492 Net income (loss) per share — basic $ 0.48 $ (0.08 ) $ 0.42 $ (0.16 ) Net income (loss) per share — diluted $ 0.48 $ (0.08 ) $ 0.42 $ (0.16 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 RSUs, stock options and ESPP to purchase common stock 16,520,200 16,907,412 16,463,459 16,907,412 Common stock warrants 17,676,679 176,679 17,676,679 176,679

Note 1 - Organization and Sum_3

Note 1 - Organization and Summary of Significant Accounting Policies (Details Textual) - USD ($) $ in Thousands		1 Months Ended	3 Months Ended	6 Months Ended		78 Months Ended
	May 31, 2022	May 31, 2022	Jun. 30, 2022	Jun. 30, 2022	Jun. 30, 2021	Mar. 31, 2022	May 30, 2019
Consideration Paid for Termination of Royalty Monetization	$ 100			$ 100		$ 100
Gain on Termination of Liability Related to Sale of Future Royalties	$ 84,100			$ 84,152	$ 0
Restructuring and Related Cost, Number of Positions Eliminated, Period Percent		40%
Severance Costs			$ 500
Loan Agreement with Oxford Finance LLC [Member]
Debt Instrument, Covenant, Minimum Required Unrestircted Cash							$ 5,000

Note 1 - Organization and Sum_4

Note 1 - Organization and Summary of Significant Accounting Policies (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021		Jun. 30, 2021	Dec. 31, 2020
Cash and cash equivalents	$ 15,165	$ 7,663	[1]	$ 21,327	$ 22,274
Restricted cash	5,000	0	[1]
Restricted cash, net of current portion	0	5,000	[1]	5,000	5,000
Total cash, cash equivalents, and restricted cash	$ 20,165	$ 12,663		$ 26,327	$ 27,274
[1]The condensed consolidated balance sheet as of December 31, 2021 has been derived from the audited financial statements as of that date included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021.

Note 2 - Investments and Fair_3

Note 2 - Investments and Fair Value Measurement (Details Textual) - USD ($) $ in Thousands	3 Months Ended			6 Months Ended		12 Months Ended
	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Other-than-temporary Impairment Loss, Debt Securities, Available-for-Sale		$ 0				$ 0
Debt Securities, Available-for-Sale, Realized Gain (Loss), Total	$ 0		$ 0	$ 0	$ 0
Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3	$ 0		$ 0	$ 0	$ 0

Note 2 - Investments and Fair_4

Note 2 - Investments and Fair Value Measurement - Summary of Cash, Cash Equivalents and Investments (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021	Jun. 30, 2021	Dec. 31, 2020
Cash and cash equivalent, fair value		$ 12,663
Total cash, cash equivalents and restricted cash	$ 20,165	12,663	$ 26,327	$ 27,274
Total cash, cash equivalents, restricted cash and short-term investments, amortized cost	27,923	51,630
Total cash, cash equivalents, restricted cash and short-term investments, fair value	27,923	51,630
Marketable Securities [Member]
Short-term investment, amortized Cost	7,758	38,967
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Short-term investment, fair value	7,758	38,967
Commercial Paper [Member] | Marketable Securities [Member]
Short-term investment, amortized Cost	7,758	29,504
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Short-term investment, fair value	7,758	29,504
Corporate Debt Securities [Member] | Marketable Securities [Member]
Short-term investment, amortized Cost		9,463
Gross Unrealized Gains		0
Gross Unrealized Losses		0
Short-term investment, fair value		9,463
Cash and Cash Equivalents [Member] | Cash [Member]
Cash, amortized cost	2,637	1,443
Cash and cash equivalent, fair value	2,637	1,443
Cash and Cash Equivalents [Member] | Money Market Funds [Member]
Cash and cash equivalent, fair value	1,150	2,822
Money market funds, amortized cost	1,150	2,822
Cash and Cash Equivalents [Member] | Commercial Paper [Member]
Cash and cash equivalent, fair value	16,378	8,398
Commercial paper, amortized cost	$ 16,378	$ 8,398

Note 2 - Investments and Fair_5

Note 2 - Investments and Fair Value Measurement - Fair Value of Financial Assets and Liabilities by Level Within Fair Value Hierarchy (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Assets, fair value	$ 25,286	$ 50,187
Liabilities, fair value	49	81
Contingent Put Option Liability [Member]
Liabilities, fair value	49	81
Fair Value, Inputs, Level 1 [Member]
Assets, fair value	1,150	2,822
Liabilities, fair value	0	0
Fair Value, Inputs, Level 1 [Member] | Contingent Put Option Liability [Member]
Liabilities, fair value	0	0
Fair Value, Inputs, Level 2 [Member]
Assets, fair value	24,136	47,365
Liabilities, fair value	0	0
Fair Value, Inputs, Level 2 [Member] | Contingent Put Option Liability [Member]
Liabilities, fair value	0	0
Fair Value, Inputs, Level 3 [Member]
Assets, fair value	0	0
Liabilities, fair value	49	81
Fair Value, Inputs, Level 3 [Member] | Contingent Put Option Liability [Member]
Liabilities, fair value	49	81
Money Market Funds [Member]
Assets, fair value	1,150	2,822
Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member]
Assets, fair value	1,150	2,822
Money Market Funds [Member] | Fair Value, Inputs, Level 2 [Member]
Assets, fair value	0	0
Money Market Funds [Member] | Fair Value, Inputs, Level 3 [Member]
Assets, fair value	0	0
Commercial Paper [Member]
Assets, fair value	24,136	37,902
Commercial Paper [Member] | Fair Value, Inputs, Level 1 [Member]
Assets, fair value	0	0
Commercial Paper [Member] | Fair Value, Inputs, Level 2 [Member]
Assets, fair value	24,136	37,902
Commercial Paper [Member] | Fair Value, Inputs, Level 3 [Member]
Assets, fair value	$ 0	0
Corporate Debt Securities [Member]
Assets, fair value		9,463
Corporate Debt Securities [Member] | Fair Value, Inputs, Level 1 [Member]
Assets, fair value		0
Corporate Debt Securities [Member] | Fair Value, Inputs, Level 2 [Member]
Assets, fair value		9,463
Corporate Debt Securities [Member] | Fair Value, Inputs, Level 3 [Member]
Assets, fair value		$ 0

Note 2 - Investments and Fair_6

Note 2 - Investments and Fair Value Measurement - Summary of Changes in Fair Value of Level III Financial Liabilities (Details) - Fair Value, Inputs, Level 3 [Member] - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Fair value, Beginning of period	$ 55	$ 181	$ 81	$ 246
Change in fair value of contingent put option associated with the Loan Agreement	(6)		(32)
Change in fair value of contingent put option associated with the Loan Agreement		(53)		(118)
Fair value, End of period	$ 49	$ 128	$ 49	$ 128

Note 3 - Inventories, Net (Deta

Note 3 - Inventories, Net (Details Textual) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
ZALVISO [Member]
Inventory Write-down	$ 0	$ 0	$ 0	$ 100

Note 3 - Inventories, Net - Inv

Note 3 - Inventories, Net - Inventory Components (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Raw materials	$ 680	$ 722
Work-in-process	0	159
Finished goods	221	230
Total	$ 901	$ 1,111	[1]
[1]The condensed consolidated balance sheet as of December 31, 2021 has been derived from the audited financial statements as of that date included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021.

Note 4 - Asset Acquisition (Det

Note 4 - Asset Acquisition (Details Textual) - USD ($) $ / shares in Units, $ in Thousands			3 Months Ended	6 Months Ended
		Jan. 07, 2022	Jun. 30, 2022	Jun. 30, 2022
In Process Research and Development [Member]
Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)			$ 0	$ 0
Lowell Therapeutics [Member]
Business Combination, Consideration Transferred, Net of Cash Acquired		$ 32,500
Cash Acquired from Acquisition		3,549
Business Combination, Options To Purchase Capital Stock Issued and Outstanding Cancelled, Exchange for Cash		$ 3,500
Business Combination, Acquiree Common Stock to Be Held Back to Satisfy Some Obligations (in shares)		1,396,526
Business Combination, Acquiree Common Stock to Be Held Back to Satisfy Some Obligations, Value	[1]	$ 800
Business Combination, Cash and Stock Paid for Transaction Costs		500
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets, Total	[2]	8,819
Business Combination, Consideration Transferred, Total		12,368
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable		6,000
Business Combination, Acquisition Related Costs		500
Payments to Acquire Businesses, Gross		3,536
Business Acquisition, Transaction Costs		2,521
Lowell Therapeutics [Member] | Contingent Consideration Payable Upon Achievement of Milestones [Member]
Business Combination, Contingent Consideration, Liability, Total		$ 26,000
Lowell Therapeutics [Member] | AcelRx Common Stock [Member]
Business Combination, Options To Purchase Capital Stock Issued and Outstanding Cancelled, Exchange for Common Stock, Number (in shares)		9,009,538
Business Combination, Acquiree Common Stock to Be Held Back to Satisfy Some Obligations, Fixed Value per Share (in dollars per share)		$ 0.57284
Business Combination, Options To Purchase Capital Stock Issued and Outstanding Cancelled, Exchange for Common Stock, Value		$ 5,200
Business Combination, Acquiree Common Stock to Be Held Back to Satisfy Some Obligations (in shares)		1,396,526
Business Combination, Acquiree Common Stock to Be Held Back to Satisfy Some Obligations, Value		$ 800
[1]Recorded as Other long-term liabilities in the Condensed Consolidated Balance Sheets.[2]Recorded as In-process research and development asset in the Condensed Consolidated Balance Sheets.

Note 4 - Asset Acquisition - Co

Note 4 - Asset Acquisition - Consideration for Acquisition (Details) - Lowell Therapeutics [Member] $ in Thousands	Jan. 07, 2022 USD ($)
Payments to Acquire Businesses, Gross	$ 3,536
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable	6,000
Business Combination, Acquiree Common Stock to Be Held Back to Satisfy Some Obligations, Value	800	[1]
Business Acquisition, Transaction Costs	2,521
Business Combination, Consideration Transferred, Total	12,368
Cash acquired	(3,549)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets, Total	8,819	[2]
Common Stock [Member]
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable	5,161
Common Stock to Settle Transaction Costs [Member]
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable	$ 350
[1]Recorded as Other long-term liabilities in the Condensed Consolidated Balance Sheets.[2]Recorded as In-process research and development asset in the Condensed Consolidated Balance Sheets.

Note 4 - Asset Acquisition - _2

Note 4 - Asset Acquisition - Consideration for Acquisition (Details) (Parentheticals)	Jan. 07, 2022 shares
Lowell Therapeutics [Member]
Business Combination, Acquiree Common Stock to Be Held Back to Satisfy Some Obligations (in shares)	1,396,526

Note 5 - Property and Equipme_3

Note 5 - Property and Equipment, Net (Details Textual) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Tangible Asset Impairment Charges, Total	$ 4,901	$ 0	$ 4,901	$ 0
Depreciation, Total	200	$ 300	500	$ 500
Zalviso-related Assets [Member]
Tangible Asset Impairment Charges, Total	$ 4,900		$ 4,900

Note 5 - Property and Equipme_4

Note 5 - Property and Equipment, Net - Components of Property and Equipment (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Property and Equipment, Gross	$ 22,368	$ 26,714
Less accumulated depreciation and amortization	(11,293)	(10,786)
Property and equipment, net	11,075	15,928	[1]
Laboratory Equipment [Member]
Property and Equipment, Gross	4,406	4,406
Leasehold Improvements [Member]
Property and Equipment, Gross	5,838	5,838
Computer Equipment and Software [Member]
Property and Equipment, Gross	1,589	1,589
Construction in Progress [Member]
Property and Equipment, Gross	9,459	13,805
Tooling [Member]
Property and Equipment, Gross	826	826
Furniture and Fixtures [Member]
Property and Equipment, Gross	$ 250	$ 250
[1]The condensed consolidated balance sheet as of December 31, 2021 has been derived from the audited financial statements as of that date included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021.

Note 6 - Revenue From Contrac_3

Note 6 - Revenue From Contracts With Customers (Details Textual) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021	Jun. 30, 2021	Dec. 31, 2020
Contract with Customer, Liability, Total	$ 1,208	$ 1,237	$ 0	$ 49
DZUVEO [Member] | Aguettant [Member]
Contract with Customer, Liability, Total	1,200
Contract with Customer, Liability, Current	$ 100

Note 6 - Revenue From Contrac_4

Note 6 - Revenue From Contracts With Customers - Disaggregation of Revenue (Details) - USD ($) $ in Thousands		3 Months Ended		6 Months Ended
		Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Revenue		$ 570	$ 443	$ 1,012	$ 954
DSUVIA [Member]
Revenue		444	392	886	573
DZUVEO [Member]
Revenue	[1]	126		126
ZALVISO [Member]
Revenue			0		270
Product [Member]
Revenue		570	392	1,012	843
Non-cash Royalty [Member]
Revenue			38		83
Royalty [Member]
Revenue			13		28
Contract and Other Collaboration [Member]
Revenue		$ 0	$ 51	$ 0	$ 111
[1]Represents sales to our partner in Europe for their expected product launch in the third quarter of 2022.

Note 6 - Revenue From Contrac_5

Note 6 - Revenue From Contracts With Customers - Contract Liability (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Balance	$ 1,237	$ 49
In current period	(29)	(49)
Balance	$ 1,208	$ 0

Note 7 - Long-term Debt (Detail

Note 7 - Long-term Debt (Details Textual) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended		6 Months Ended
	Aug. 01, 2019	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021	May 30, 2019
Amortization of Debt Discount (Premium)				$ 250	$ 430
Total Obligation Under Leasehold Agreement		$ 500		500
Leasehold Improvements, Gross		$ 1,700		$ 1,700		$ 1,700
Site Readiness Agreement [Member]
Debt Instrument, Periodic Payment, Principal	$ 500
Total Obligation Under Leasehold Agreement						500
Debt Instrument, Interest Rate, Effective Percentage		14.40%		14.40%
Warrant In Connection with Oxford Finance Loan Agreement [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)							176,679
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)							$ 2.83
Loan Agreement with Oxford Finance LLC [Member]
Debt Instrument, Face Amount							$ 25,000
Debt Instrument, Covenant, Minimum Required Unrestircted Cash							$ 5,000
Long-Term Debt, Total		$ 9,400		$ 9,400		$ 13,300
Interest Expense, Debt, Total		300	$ 600	700	1,200
Amortization of Debt Discount (Premium)		$ 100	$ 200	$ 200	$ 400

Note 8 - Leases (Details Textua

Note 8 - Leases (Details Textual) - USD ($)	Mar. 26, 2021	Jun. 30, 2022	Dec. 31, 2021	[1]
Operating Lease, Right-of-Use Asset		$ 3,985,000	$ 4,302,000
Lease for Corporate Headquarters in Hayward, California [Member]
Lessee, Operating Lease, Term of Contract (Year)	2 years 3 months
Lessee, Operating Lease, Monthly Rent	$ 17,000
Lessee, Operating Lease, Abated Rent Period (Month)	1 month
Operating Lease, Right-of-Use Asset	$ 400,000
[1]The condensed consolidated balance sheet as of December 31, 2021 has been derived from the audited financial statements as of that date included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021.

Note 8 - Leases - Operating Lea

Note 8 - Leases - Operating Lease Costs (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Operating lease costs	$ 343	$ 440	$ 686	$ 780
Gain on derecognition of operating lease	0	0	0	(522)
Sublease income	0	(50)	0	(199)
Loss on termination of sublease	0	331	0	331
Net lease costs	$ 343	$ 721	$ 686	$ 390
Weighted-average remaining lease term – operating leases (years) (Year)	4 years 6 months 25 days	5 years 4 months 28 days	4 years 6 months 25 days	5 years 4 months 28 days
Weighted-average remaining discount rate – operating leases	12.80%	12.80%	12.80%	12.80%

Note 8 - Leases - Maturities of

Note 8 - Leases - Maturities of Lease Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021	[1]
2022 (remaining six months)	$ 921
2023	1,344
2024	1,040
2025	1,040
2026	1,040
Thereafter	415
Total future minimum lease payments	5,800
Less imputed interest	(1,299)
Total	4,501
Operating lease liabilities	4,501
Operating lease liabilities, current portion	(1,142)	$ (1,068)
Operating lease liabilities, net of current portion	$ 3,359	$ 3,750
[1]The condensed consolidated balance sheet as of December 31, 2021 has been derived from the audited financial statements as of that date included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021.

Note 9 - Liability Related to_3

Note 9 - Liability Related to Sale of Future Royalties (Details Textual) - USD ($) $ in Thousands			3 Months Ended		6 Months Ended		78 Months Ended
	May 31, 2022	Sep. 18, 2015	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Mar. 31, 2022
Proceeds From Sale of Royalty and Milestone Rights		$ 65,000
Consideration Paid for Termination of Royalty Monetization	$ 100				$ 100		$ 100
Gain on Termination of Liability Related to Sale of Future Royalties	$ 84,100				$ 84,152	$ 0
Effective Annual Interest Rate			3.20%	3.60%	3.20%	3.60%
SWK [Member]
Percentage of Royalties and Rights Under Agreement		75%
SWK [Member] | First Four Commercial Milestones [Member]
Percentage of Royalties and Rights Under Agreement		80%
Commercial Milestones Value Maximum Amount Available		$ 35,600
AcelRX [Member] | First Four Commercial Milestones [Member]
Commercial Milestones Value Maximum Amount Available		$ 44,500

Note 9 - Liability Related to_4

Note 9 - Liability Related to Sale of Future Royalties - Activity of Liability Related to Sale of Future Royalties (Details) - USD ($) $ in Thousands		3 Months Ended		6 Months Ended		78 Months Ended
	May 31, 2022	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Mar. 31, 2022
Liability related to sale of future royalties — beginning balance				$ 85,288		$ 0
Proceeds from sale of future royalties				0		61,184
Non-cash royalty revenue				0		(1,083)
Non-cash interest (income) expense recognized		$ (463)	$ (799)	(1,136)	$ (1,581)	24,051
Consideration paid for termination of Royalty Monetization	$ (100)			(100)		(100)
Gain on termination of liability related to sale of future royalties		(84,052)	$ 0	(84,052)	$ 0	(84,052)
Liability related to sale of future royalties as of June 30, 2022		$ 0		$ 0		$ 0

Note 10 - Commitments and Con_2

Note 10 - Commitments and Contingencies (Details Textual)	Jul. 06, 2021	Jun. 08, 2021
Purported Shareholder v. Company - Violation of Sections 10(b) and 20(a) of the Exchange Act and SEC Rule 10b-5 [Member]
Loss Contingency, Number of Defendants		2
Purported Shareholder v. Company - Alleged Misstatements as the Shareholder [Member]
Loss Contingency, Number of Defendants	10

Note 11 - Stockholders' Equity

Note 11 - Stockholders' Equity (Details Textual) - USD ($) shares in Thousands, $ in Thousands		3 Months Ended		6 Months Ended
	May 09, 2019	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Proceeds from Issuance of Common Stock				$ 0	$ 36,360
ATM Agreement [Member]
Aggregate Offering Price, Maximum	$ 80,000			$ 36,100
Stock Issued During Period, Shares, New Issues (in shares)		0	3,000	0	3,000
Proceeds from Issuance of Common Stock			$ 7,500		$ 7,500

Note 12 - Stock-based Compens_3

Note 12 - Stock-based Compensation (Details Textual)	3 Months Ended	6 Months Ended
	Jun. 30, 2022 shares	Jun. 30, 2022 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share) | $ / shares		$ 0.30
The 2020 Equity Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)	6,352,183	6,352,183
Amended ESPP [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)	4,302,929	4,302,929
Restricted Stock Units (RSUs) [Member]
Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation (in shares)	0	141,966

Note 12 - Stock-based Compens_4

Note 12 - Stock-based Compensation - Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Stock-based compensation expense	$ 753	$ 1,172	$ 1,536	$ 2,261
Cost of Sales [Member]
Stock-based compensation expense	16	21	35	43
Research and Development Expense [Member]
Stock-based compensation expense	153	200	327	381
Selling, General and Administrative Expenses [Member]
Stock-based compensation expense	$ 584	$ 951	$ 1,174	$ 1,837

Note 12 - Stock-based Compens_5

Note 12 - Stock-based Compensation - Restricted Stock Activity (Details) - Restricted Stock Units (RSUs) [Member]	6 Months Ended
	Jun. 30, 2022 $ / shares shares
Restricted stock units outstanding (in shares) | shares	1,774,376
Restricted stock units weighted average outstanding (in dollars per share) | $ / shares	$ 1.71
Granted (in shares) | shares	1,061,826
Weighted average grant date fair value, granted (in dollars per share) | $ / shares	$ 0.40
Vested (in shares) | shares	(880,315)
Weighted average grant date fair value, vested (in dollars per share) | $ / shares	$ 1.78
Forfeited (in shares) | shares	(313,288)
Weighted average grant date fair value, forfeited (in dollars per share) | $ / shares	$ 1.29
Restricted stock units outstanding (in shares) | shares	1,642,599
Restricted stock units weighted average outstanding (in dollars per share) | $ / shares	$ 0.91

Note 12 - Stock-based Compens_6

Note 12 - Stock-based Compensation - Option Activity (Details) $ / shares in Units, $ in Thousands	6 Months Ended
	Jun. 30, 2022 USD ($) $ / shares shares
Outstanding (in shares) | shares	14,284,050
Outstanding (in dollars per share) | $ / shares	$ 2.99
Granted (in shares) | shares	2,123,650
Granted, weighted-average exercise price (in dollars per share) | $ / shares	$ 0.40
Forfeited (in shares) | shares	(552,745)
Forfeited, weighted-average exercise price (in dollars per share) | $ / shares	$ 1.37
Expired (in shares) | shares	(812,693)
Expired, weighted-average exercise price (in dollars per share) | $ / shares	$ 3.31
Exercised (in shares) | shares	0
Exercised, weighted-average exercise price (in dollars per share) | $ / shares	$ 0
Outstanding (in shares) | shares	15,042,262
Outstanding, weighted-average exercise price (in dollars per share) | $ / shares	$ 2.67
Outstanding, weighted-average remaining contractual life (Year)	5 years 9 months 18 days
Outstanding, aggregate intrinsic value | $	$ 0
Vested and exercisable options (in shares) | shares	10,473,947
Vested and exercisable options, weighted-average exercise price (in dollars per share) | $ / shares	$ 3.31
Vested and exercisable options, weighted-average remaining contractual life (Year)	4 years 6 months
Vested and exercisable options, aggregate intrinsic value | $	$ 0
Vested and expected to vest (in shares) | shares	15,042,262
Vested and expected to vest, weighted-average exercise price (in dollars per share) | $ / shares	$ 2.67
Vested and expected to vest, weighted-average remaining contractual life (Year)	5 years 9 months 18 days
Vested and expected to vest, aggregate intrinsic value | $	$ 0

Note 12 - Stock-based Compens_7

Note 12 - Stock-based Compensation - Assumptions to Calculate Fair Value of Each Performance-based Stock Option (Details) - Performance Shares [Member]	6 Months Ended
	Jun. 30, 2022
Expected term (in years) (Year)	6 years 3 months 18 days
Expected volatility	88%
Expected dividend rate	0%
Minimum [Member]
Risk-free interest rate	1.60%
Maximum [Member]
Risk-free interest rate	2.20%

Note 13 - Net Income (Loss) P_3

Note 13 - Net Income (Loss) Per Share of Common Stock - Computation of Basic and Diluted Net Income (Loss) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2022	Jun. 30, 2021
Net income (loss)	$ 70,663	$ (8,674)	$ (9,851)	$ (8,956)	$ 61,989	$ (18,807)
Weighted average shares outstanding — basic (in shares)	147,139,032		119,120,040		146,385,577	116,204,492
Dilutive effect of RSUs (in shares)	70,033		0		34,860	0
Weighted average shares outstanding — diluted (in shares)	147,209,065		119,120,040		146,420,437	116,204,492
Net income (loss) per share — basic (in dollars per share)	$ 0.48		$ (0.08)		$ 0.42	$ (0.16)
Net income (loss) per share — diluted (in dollars per share)	$ 0.48		$ (0.08)		$ 0.42	$ (0.16)

Note 13 - Net Income (Loss) P_4

Note 13 - Net Income (Loss) Per Share of Common Stock - Common Stock Excluded From Computation of Diluted Net Loss Per Share (Details) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
RSU's, ESPP, and Employee Stock Options [Member]
Antidilutive securities (in shares)	16,520,200	16,907,412	16,463,459	16,907,412
Warrant [Member]
Antidilutive securities (in shares)	17,676,679	176,679	17,676,679	176,679

Note 14 - Subsequent Event (Det

Note 14 - Subsequent Event (Details Textual) - Subsequent Event [Member]	Aug. 03, 2022 USD ($) $ / shares shares
Warrants Issued with Securities Purchase Agreement [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares	1,623,008
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares	$ 0.2033
Securities Purchase Agreement [Member]
Proceeds from Issuance or Sale of Equity, Total | $	$ 300,000
Securities Purchase Agreement [Member] | Series A Preferred Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares) | shares	3,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares	$ 0.001